Tags
Language
Tags

2022 Nelson's Pediatric Antimicrobial Therapy, 28th Edition

Posted By: yoyoloit
2022 Nelson's Pediatric Antimicrobial Therapy, 28th Edition

2022 Nelson's Pediatric Antimicrobial Therapy
by Bradley, John S.;Nelson, John D.;Elizabeth, Barnett;Cantey, Joseph B.;Kimberlin, David W.;Palumbo, Paul E.;Sauberan, Jason;Smart, J. Howard;Steinbach, William J.;

English | 2022 | ISBN: ‎ 1610025644, 978-1610025645 | 382 pages | True PDF | 3.55 MB

Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children.

For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.

TOPICS INCLUDE

Antimicrobial Therapy by Clinical Syndromes
Antimicrobial Therapy for Neonates
Choosing Among
Antibiotics
Antifungal Agents
Antiviral Agents
Antiparasitic Agents
Oral Step-down Therapy for Serious Infections
Prevention of Symptomatic Infection
Approach to Antibiotic Allergies
Antibiotic Stewardship
New in the 28th Edition
Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections
Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021–2022
Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase–producing enteric bacilli, if susceptible
Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in children
New dosing for posaconazole suspension formulation
New approaches to mucormycosis
Added baloxavir for children 12+ years old